Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard,
Suite 700
Pasadena
California
91101
United States
499 articles with Arrowhead Pharmaceuticals, Inc.
-
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
3/20/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
-
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
3/3/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston.
-
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
2/28/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.
-
Arrowhead Pharmaceuticals has gained full rights to ARO-PNPLA3, formerly JNJ-75220795, the company announced Wednesday.
-
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
2/15/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
2/6/2023
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
2/2/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
1/25/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
-
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
1/9/2023
Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
-
Takeda and Arrowhead Pharmaceuticals’ Phase II trial studying fazirsiran, an investigational RNA therapeutic developed for AATD-LD, was effective in Phase II–but so was the placebo.
-
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
12/21/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda.
-
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
12/21/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023, at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco.
-
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
12/20/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN).
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 15, 2022
12/15/2022
Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 9, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 35 new employees under Rule 5635 of the NASDAQ Listing Rules.
-
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
12/8/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457.
-
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
11/28/2022
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.
-
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences - November 21, 2022
11/21/2022
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming investor events.
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
11/14/2022
Arrowhead Pharmaceuticals Inc. announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022.
-
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
11/9/2022
Arrowhead Pharmaceuticals Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
-
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
11/7/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new clinical data on its pipeline of investigational RNAi-based cardiometabolic medicines, ARO-APOC3, ARO-ANG3, and olpasiran, which is being developed by Amgen, in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago.